Noa Krawczyk, PhD
NYU Langone Health, Division of Epidemiology, Center for Opioid Epidemiology and Policy, Department of Population Health - Assistant Professor
Email: noa.krawczyk@nyulangone.org
Education
PhD, Mental Health, Johns Hopkins Bloomberg School of Public HealthBA, Biology, Hunter College at the City University of New York – Macaulay Honors College
Research Interests
Substance use, Opioids, Overdose, Health services, Mental health, Criminal justice, Treatment BIO
Noa Krawczyk is an Assistant Professor in the Department of Population Health at NYU School of Medicine and a member of the Center for Opioid Epidemiology and Policy. She completed her PhD in the Department of Mental Health at the Johns Hopkins Bloomberg School of Public Health, where she studied substance use epidemiology, and previously worked as a Fulbright research scholar to study treatment and health services among cocaine users in Brazil. Her research focuses on studying ways to address barriers to evidence-based treatment for opioid use disorders and improving quality and effectiveness of care, especially among vulnerable groups such as persons with criminal justice involvement. Her work centers on bridging research and practice by collaborating with health organizations, public health and government agencies and advancing science that can help inform evidence-based policies and practices that reduce harm and promote long term recovery. Projects
Principal Investigator, Beyond Treatment Initiation: Enhancing Opioid Use Disorder Care Transitions Across Health System Touchpoints. Active
Principal Investigator, Simulating the Impact of Office-Based Methadone Prescribing and Pharmacy Dispensing on OUD Treatment and Overdose in New York State: An Agent-Based Modeling Approach. Active
Principal Investigator, Trends in Psychosis Related to Hospitalizations Among Youth Following Cannabis Legalization in Colorado. Completed
Publications
Recent
Cerda M, Krawczyk N (2024).
The US overdose crisis: The next administration needs to move beyond criminalisation to a comprehensive public health approach
BMJ, 387, q2418. doi: 10.1136/bmj.q2418.
The US overdose crisis: The next administration needs to move beyond criminalisation to a comprehensive public health approach
BMJ, 387, q2418. doi: 10.1136/bmj.q2418.
Ross RK, Nunes EV, Olfson M, Shulman M, Krawczyk N, Stuart EA, Rudolph KE (2024).
Comparative effectiveness of extended-release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients
Addiction, 119 (11), 1975-1986. doi: 10.1111/add.16630. PMCID: PMC11479822.
Comparative effectiveness of extended-release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients
Addiction, 119 (11), 1975-1986. doi: 10.1111/add.16630. PMCID: PMC11479822.
Krawczyk N, Miller M, Englander H, Rivera BD, Schatz D, Chang J, Cerda M, Berry C, McNeely J (2024).
Toward a consensus on strategies to support opioid use disorder care transitions following hospitalization: A modified Delphi process
Journal of General Internal Medicine [Epub 2024 Oct 22]. doi: 10.1007/s11606-024-09108-8.
Toward a consensus on strategies to support opioid use disorder care transitions following hospitalization: A modified Delphi process
Journal of General Internal Medicine [Epub 2024 Oct 22]. doi: 10.1007/s11606-024-09108-8.
Feder KA, Li YZ, Burke KN, Byrne L, Desai IK, Saloner B, Krawczyk N (2024).
Client and program-level factors associated with planned use of medications for opioid use disorder in specialty substance use treatment programs: Evidence from linked administrative data and survey data
Journal of Substance Use and Addiction Treatment [Epub 2024 Oct 21]. doi: 10.1016/j.josat.2024.209545.
Client and program-level factors associated with planned use of medications for opioid use disorder in specialty substance use treatment programs: Evidence from linked administrative data and survey data
Journal of Substance Use and Addiction Treatment [Epub 2024 Oct 21]. doi: 10.1016/j.josat.2024.209545.
Shearer R, Hagedorn H, Englander H, Siegler T, Kibben R, Fawole A, Patten A, Fitzpatrick A, Laes J, Fernando J, Appleton N, Oot E, Titus H, Krawczyk N, Weinstein Z, McNeely J, Baukol P, Ghitza U, Gustafson D, Bart G, Bazzi A (2024).
Barriers and facilitators to implementing treatment for opioid use disorder in community hospitals
Journal of Substance Use and Addiction Treatment, 167, 209520. doi: 10.1016/j.josat.2024.209520.
Barriers and facilitators to implementing treatment for opioid use disorder in community hospitals
Journal of Substance Use and Addiction Treatment, 167, 209520. doi: 10.1016/j.josat.2024.209520.
Notable
Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap
Journal of Substance Abuse Treatment, 103, 1-8. doi: 10.1016/j.jsat.2019.05.002. PMCID: PMC6612429.
Krawczyk N, Picher CE, Feder KA, Saloner B (2017).
Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine
Health Affairs, 36 (12), 2046-2053. doi: 10.1377/hlthaff.2017.0890. PMCID: PMC6035729.
Dr. Krawczyk's MyBibliography Profile
Selected Press